Monday, September 1, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Clinical Trial Suggests Menopause Drug Duavee Could Help Prevent Invasive Breast Cancer

May 29, 2025
in Cancer
Reading Time: 4 mins read
0
66
SHARES
597
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

A Common Menopause Drug Shows Promise in Preventing Invasive Breast Cancer

An innovative clinical trial spearheaded by researchers at Northwestern Medicine has revealed unexpected potential for a drug already approved to treat menopausal symptoms. The findings, soon to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, suggest that Duavee — a combination therapy of conjugated estrogens and bazedoxifene — could slow the progression of certain pre-invasive breast lesions, potentially preventing the evolution into invasive breast cancer.

Duavee’s dual action tackles menopausal discomfort while exhibiting biologically significant effects on breast tissue. Postmenopausal women diagnosed with ductal carcinoma in situ (DCIS), a non-invasive breast condition widely regarded as a precursor to invasive breast cancer, participated in the trial. DCIS affects approximately 60,000 women annually in the United States alone, representing a substantial population at risk. This phase 2 trial randomized 141 women across ten clinical sites to receive either Duavee or a placebo during a critical window between diagnosis and surgical intervention.

The scientific rationale behind this study centers on the modulation of hormone receptors in breast tissue. Estrogens influence cellular proliferation, and selective estrogen receptor modulators like bazedoxifene are designed to mitigate estrogen’s unwanted effects in the breast while providing beneficial effects elsewhere in the body, such as bone preservation. By combining these agents, Duavee offers a nuanced hormonal environment that was observed to reduce markers indicative of cellular proliferation in breast tissue samples, which are highly predictive of the risk of malignant transformation.

According to Dr. Swati Kulkarni, the lead investigator and a professor of breast surgery at Northwestern University Feinberg School of Medicine, the reduction in cell growth rates observed in the Duavee-treated group is a promising biomarker change indicative of hindered cancer progression pathways. This represents a significant breakthrough as current medications for breast cancer prevention often involve considerable side effects that lead many women to forego prophylactic treatment.

Critically, Duavee’s tolerability profile in this trial appeared favorable. Unlike other hormone-based preventive therapies known for inducing menopausal symptom exacerbation or other systemic side effects, participants receiving Duavee did not report a decline in quality of life. This tolerability could lead to improved adherence and acceptance among women facing the challenge of balancing menopausal management with breast cancer risk reduction.

The target population for this intervention encompasses women with a history of high-risk breast lesions, including atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS), as well as prior diagnoses of DCIS. These conditions elevate the lifetime risk of invasive breast cancer substantially. Women in this demographic group typically have limited options for hormone therapy during menopause due to concerns about triggering cancerous changes, making Duavee a potentially valuable therapeutic alternative.

The mechanism by which Duavee affects breast tissue involves selective modulation at the estrogen receptor level. Conjugated estrogens provide hormone replacement to alleviate menopausal symptoms, while bazedoxifene acts as an estrogen receptor antagonist specifically in breast and uterine tissue, preventing potential proliferative effects. This complex interplay may disrupt the estrogen-driven pathways responsible for cellular overgrowth, thereby curbing neoplastic progression without compromising systemic estrogen benefits.

This trial’s methodology included administering Duavee or placebo for approximately four weeks, a relatively brief preoperative period allowing precise examination of acute biological effects on breast tissue sampled during surgery. Despite the short duration, the significant decrease in cell proliferation markers underscores a robust biological response, suggesting the potential for even greater benefits with extended therapy, pending future studies.

While these results are compelling, Dr. Kulkarni emphasizes the necessity for larger scale trials with extended follow-up to validate long-term efficacy and safety before recommending Duavee as a standard preventive therapy. The existing FDA approval and widespread clinical availability of Duavee, however, expedite the potential translational impact should future research corroborate these findings.

The broader implications of this research are profound, as it bridges menopausal symptom management and cancer prevention—two domains often treated disparately despite their clinical intersection. The availability of a well-tolerated, dual-purpose medication could revolutionize the approach to care in a vulnerable demographic of postmenopausal women at elevated breast cancer risk.

This study also exemplifies the value of repurposing existing drugs with well-characterized safety profiles, potentially accelerating access to new clinical applications without the lengthy drug development timelines typically required. Such strategies are especially important in oncology, where prevention remains a critical yet underutilized avenue.

In summary, the Northwestern-led clinical trial presents a promising new frontier in breast cancer prevention. Duavee’s ability to slow cellular proliferation in DCIS lesions, coupled with its menopausal symptom relief and favorable side effect profile, highlights its potential as a transformative option. As more comprehensive data emerges, this therapy may become a cornerstone in reducing invasive breast cancer incidence among high-risk postmenopausal women, ultimately improving both longevity and quality of life.


Subject of Research: The investigation into Duavee’s effectiveness in preventing invasive breast cancer progression in postmenopausal women with DCIS.

Article Title: Common Menopause Drug Duavee Shows Potential to Prevent Invasive Breast Cancer in High-Risk Women

News Publication Date: June 1, 2025

Web References:

  • Northwestern Medicine Faculty Profile: Dr. Swati Kulkarni
  • Clinical Trial Registration: NCT02694809
  • ASCO Annual Meeting Presentation Details: ASCO 2025 Meeting
  • Breast Cancer Research Foundation on DCIS: About DCIS

Keywords: Breast cancer, DCIS, menopausal symptoms, hormone therapy, conjugated estrogens, bazedoxifene, hormone receptor modulation, cancer prevention, selective estrogen receptor modulator, postmenopausal women, cell proliferation, hormonal biology.

Tags: ASCO Annual Meeting 2025bazedoxifene therapybreast cancer risk reductionclinical trial findingsDuavee menopause drugductal carcinoma in situestrogen receptor modulatorshormone receptor modulationinnovative cancer therapiesinvasive breast cancer preventionmenopausal symptom treatmentpostmenopausal women health
Share26Tweet17
Previous Post

Unraveling the Interfacial Chemistry and Role of Organic Additives in Superconformal Cobalt Electrodeposition

Next Post

An Affordable and Accessible Approach to Reducing Carbon Emissions in Maritime Shipping

Related Posts

blank
Cancer

Study Reveals Antineoplastic Therapy Adherence in Lung Cancer

September 1, 2025
blank
Cancer

Growth, Ki-67, Immunity in Lung Nodules

August 31, 2025
blank
Cancer

Global Ovarian Cancer Burden: 1990-2050 Insights

August 31, 2025
blank
Cancer

Improving Patient Care for Chemotherapy-Induced Mucositis

August 31, 2025
blank
Cancer

U2AF1 Mutation Impacts Erythroid Differentiation, Drug Response

August 31, 2025
blank
Cancer

Propranolol’s Potential Role in Cancer Treatment Explored

August 31, 2025
Next Post
blank

An Affordable and Accessible Approach to Reducing Carbon Emissions in Maritime Shipping

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27542 shares
    Share 11014 Tweet 6884
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    956 shares
    Share 382 Tweet 239
  • Bee body mass, pathogens and local climate influence heat tolerance

    642 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    509 shares
    Share 204 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    313 shares
    Share 125 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Augmented Reality and Haptics Enhance Lumbar Puncture Training
  • Mini Percutaneous Nephrolithotomy: IAU Best Practice Insights
  • Microalgae Combat Antibiotic Resistance in Wastewater
  • Optimizing Aluminum Ski Laminate Stiffness with Soft Materials

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,182 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading